"Substantia Nigra" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The black substance in the ventral midbrain or the nucleus of cells containing the black substance. These cells produce DOPAMINE, an important neurotransmitter in regulation of the sensorimotor system and mood. The dark colored MELANIN is a by-product of dopamine synthesis.
| Descriptor ID |
D013378
|
| MeSH Number(s) |
A08.186.211.132.659.413.656
|
| Concept/Terms |
Substantia Nigra- Substantia Nigra
- Nigra, Substantia
- Nigras, Substantia
- Substantia Nigras
|
Below are MeSH descriptors whose meaning is more general than "Substantia Nigra".
Below are MeSH descriptors whose meaning is more specific than "Substantia Nigra".
This graph shows the total number of publications written about "Substantia Nigra" by people in this website by year, and whether "Substantia Nigra" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 1 | 2 |
| 1995 | 2 | 1 | 3 |
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 0 | 2 | 2 |
| 1999 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2004 | 2 | 0 | 2 |
| 2005 | 2 | 1 | 3 |
| 2006 | 2 | 2 | 4 |
| 2007 | 1 | 1 | 2 |
| 2008 | 3 | 3 | 6 |
| 2009 | 1 | 1 | 2 |
| 2010 | 1 | 1 | 2 |
| 2011 | 0 | 3 | 3 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 2 | 1 | 3 |
| 2015 | 1 | 1 | 2 |
| 2017 | 1 | 2 | 3 |
| 2018 | 2 | 0 | 2 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Substantia Nigra" by people in Profiles.
-
Inhibition of Calpain Attenuates Degeneration of Substantia Nigra Neurons in the Rotenone Rat Model of Parkinson's Disease. Int J Mol Sci. 2022 Nov 10; 23(22).
-
Calpain activation and progression of inflammatory cycles in Parkinson's disease. Front Biosci (Landmark Ed). 2022 01 13; 27(1):20.
-
Cellular and molecular pathophysiology in the progression of Parkinson's disease. Metab Brain Dis. 2021 06; 36(5):815-827.
-
Cell-Permeable Calpain Inhibitor SJA6017 Provides Functional Protection to Spinal Motoneurons Exposed to MPP. Neurotox Res. 2020 Oct; 38(3):640-649.
-
Differential effects of vagus nerve stimulation paradigms guide clinical development for Parkinson's disease. Brain Stimul. 2020 Sep - Oct; 13(5):1323-1332.
-
Effects of vagus nerve stimulation are mediated in part by TrkB in a parkinson's disease model. Behav Brain Res. 2019 11 05; 373:112080.
-
Acute sensitivity of astrocytes in the Substantia Nigra to oxygen and glucose deprivation (OGD) compared with hippocampal astrocytes in brain slices. Neurosci Lett. 2018 10 15; 685:137-143.
-
Cre-dependent AAV vectors for highly targeted expression of disease-related proteins and neurodegeneration in the substantia nigra. FASEB J. 2018 08; 32(8):4420-4427.
-
5-HT1F receptor-mediated mitochondrial biogenesis for the treatment of Parkinson's disease. Br J Pharmacol. 2018 01; 175(2):348-358.
-
Vagus nerve stimulation improves locomotion and neuronal populations in a model of Parkinson's disease. Brain Stimul. 2017 Nov - Dec; 10(6):1045-1054.